1stOncology™: Cancer Intelligence Service – Page 8597 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021

On September 1, 2021 Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, reported its participation in the following medical and investor conferences (Press release, Aeglea BioTherapeutics, SEP 1, 2021, View Source [SID1234587130]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Investor Meetings

2021 Wells Fargo Virtual Healthcare Conference, September 9
H.C. Wainwright 23rd Annual Global Investment Conference, September 13
2021 Cantor Virtual Global Healthcare Conference, September 27
Medical Conferences

International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2021), September 17 – 22
50th Child Neurology Society (CNS) Annual Meeting, September 29 – October 2
At both the MDS Virtual Congress and the CNS Annual Meeting, a poster presentation will outline a subset analysis from the Company’s previously reported Phase 1/2 and Phase 2 open label extension studies of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). In the poster, analysis of gait kinematics and spasticity was completed using video compilations.

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company’s website. A replay of Company webcasts is archived on the website for 30 days following presentations.

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

On September 1, 2021 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center reported a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch (Press release, Bellicum Pharmaceuticals, SEP 1, 2021, View Source [SID1234587106]). Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.

Bellicum’s CaspaCIDe safety switch may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next-generation higher potency cell therapy constructs.

"We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients," said Rick Fair, President and CEO of Bellicum Pharmaceuticals. "We believe that our switch technology may enhance the benefit/risk profile of cell therapies. We intend to continue to pursue opportunities to expand its use via external collaborations with other leaders in the field."

Upon exercise of each option – typically expected to be upon out-license of an MD Anderson program that incorporates iC9 – Bellicum will receive an upfront payment and will be entitled to a percentage of certain consideration paid to MD Anderson by the third party. Bellicum also will receive a single-digit-percent royalty on global sales of the product. Additional details of the financial arrangements are not disclosed. Bellicum and MD Anderson have agreed on the first two programs for development concurrent with the execution of the agreement. This agreement expands upon a previous one, which covers the use of CaspaCIDe in a specific MD Anderson cell therapy program.

"The unique inducible caspase-9 technology covered by this agreement has the potential to reduce the risk of serious adverse events associated with cellular therapies and to improve patient outcomes," said Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson. "We have successfully applied the technology to existing cell therapies, and we look forward to the potential future applications made possible by this agreement."

About CaspaCIDe

CaspaCIDe (inducible caspase-9, or iC9) is Bellicum’s chemical induction of dimerization (CID) safety switch technology designated to eliminate cells in the event of toxicity. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9, an enzyme that is part of the apoptotic pathway. Infusion of rimiducid is designed to trigger activation of this domain of caspase-9, which in turn leads to selective apoptosis of the CaspaCIDe-containing cells. In clinical studies, use of CaspaCIDe has resulted in clinical improvement in most patients as early as 24 hours after rimiducid administration. Further, because CaspaCIDe is designed to be permanently incorporated into Bellicum’s cellular therapies, the safety switch has the potential to be available for use when needed long after the initial therapy is delivered.

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

On September 1, 2021 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported that Bill Newell, Chief Executive Officer, will participate in the 2021 Wells Fargo Securities Healthcare Conference during a virtual fireside chat on Thursday, September 9, at 3:20 p.m. ET / 12:20 p.m. PT (Press release, Sutro Biopharma, SEP 1, 2021, View Source [SID1234587129]).

A live webcast of the presentation will be accessible through the News and Events page of the Investor Relations section on the company’s website at www.sutrobio.com. Archived replays of the webcasts will be available on the company’s website for approximately 30 days following each live presentation.

Evogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference – 2021

On September 1, 2021 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, reported that Ofer Haviv, Evogene’s President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, 2021, taking place from September 9-15, 2021 (Press release, Evogene, SEP 1, 2021, https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-23rd-annual-global-investment-conference—2021-301367032.html [SID1234587128]). Mr. Haviv’s presentation will focus on Evogene’s disruptive technologies, its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries, and will take place on Thursday September 9, 2021, at 07:30 am, EST.

Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene’s Investor Relations team at [email protected] or through the conference’s online meeting platform.

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

On September 1, 2021 OncoQuest Pharmaceuticals Inc., ("OncoQuest") a clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer, reported the first patient enrolled in each of two investigator initiated clinical trials assessing the safety and efficacy of oregovomab in a previously treated recurrent ovarian cancer setting (Press release, OncoQuest, SEP 1, 2021, View Source [SID1234587126]).

The first study, led byProf. Jung KH, is being conducted at three centres in Korea (Korea Anam Hospital, Seoul St. Mary’s Hospital and Seoul Asan Hospital). This is a Phase 1b/2 clinical trial evaluation of the safety and efficacy of oregovomab when used in combination with bevacizumab, paclitaxel, and carboplatin in subjects with platinum sensitive recurrent ovarian cancer. Oregovomab has previously been established to augment the activity of carboplatin and paclitaxel through immune stimulation, and bevacizumab augments the activity of carboplatin and paclitaxel by inhibiting angiogenesis. The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583). This study is supported by Korean Government’s K-Master program (KM-21) under the guidance of Prof. Kim YH at the Korea University Anam Hospital and Professor Park KH at Korea University College of Medicine.

The second study (ORION-02), led by Clinical Assistant Professor Jack Chan, is being conducted at a single centre in Singapore (National Cancer Centre Singapore). This is a Phase 1/2 clinical trial evaluation of the safety and efficacy of platinum-based chemotherapy, oregovomab and the PD-1 blockade agent, nivolumab, in subjects with platinum sensitive recurrent epithelial cancer of ovarian, tubal, or peritoneal origin (ClinicalTrials.gov Identifier: NCT04620954). The safety of oregovomab in combination with nivolumab has already been established in the ORION-01 study (ClinicalTrials.gov Identifier: NCT03100006).

OncoQuest has completed a Phase II study using oregovomab in combination with a TLR-3 agonist (Hiltonol) in the recurrent ovarian cancer setting (ClinicalTrials.gov Identifier: NCT03162562). Oregovomab is currently being tested in a global Phase III study in 12 countries in combination with carboplatin and paclitaxel chemotherapy in the front-line ovarian cancer setting (ClinicalTrials.gov Identifier: NCT04498117).

"We are committed to continue to work with investigators to explore the potential of oregovomab in combination therapies for treating ovarian cancer in both front line and recurrent settings. Progress in this area began in collaboration with Dr. Alan Gordon (Gynecologic Oncology2004 94:340-351) that identified potential favourable interactions between oregovomab and both carboplatin and doxorubicin in the recurrent disease setting. Those initial results led eventually to the observations recently reported by Brewer et al (Gynecologic Oncology 2020 156:523-529) that combining oregovomab with carboplatin and paclitaxel in a front-line setting improves outcomes", said Dr. Madiyalakan, Chairman of OncoQuest. OncoQuest is also in the process of initiating a clinical trial using oregovomab with niraparib in the recurrent ovarian cancer setting. "These additional clinical studies will guide us to select the optimal combinations for treatment throughout the course of this difficult disease," added Dr. Madiyalakan.

About Oregovomab.

Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase 2 trial. In a randomized Phase 2 clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Clinical and translational results were published in Gynecologic Oncology (2020 156:523-529) and Cancer Immunology and Immunotherapy (2020 69: 383-397), respectively.